Ironwood Pharmaceuticals heads into its third-quarter report with an odd disconnect. Three months ago management raised every major piece of its 2026 outlook, lifted its Linzess demand forecast and collected a pediatric approval. Since then the stock has fallen 13.2% while the S&P 500 barely moved. The report due before the open on November 5 should show whether the market is wrong about the business or right to worry about what comes after 2026.
The Street is looking for earnings of $0.30 a share on revenue of $149.3 million, which would be gains of 25% and 22.3% from a year earlier. That is strong growth, and the revenue figure is a big sequential jump from the $113.0 million reported last quarter. The per-share estimate, however, sits slightly below the prior quarter's $0.31. That tells you analysts expect the higher top line to be partly absorbed by rising costs, which is exactly what management told them to expect. Full-year revenue consensus of about $473 million lands almost exactly at the midpoint of the raised $460 million to $485 million guidance range. The Street has accepted the raise but is not betting on another one.
The central operating question is Linzess demand. Management moved its full-year demand outlook to mid-single-digit growth from low-single-digit, after second-quarter prescriptions grew 4% and the year-to-date pace reached 5%. Just as important, it said it no longer expected Medicaid volumes to soften after the elimination of inflationary rebates, a risk that had hung over the prior two calls. A third quarter that keeps demand growth in that mid-single-digit zone, with Linzess U.S. net sales tracking toward the $1.15 billion to $1.2 billion range, would validate the upgrade. Any sign that Medicaid volume erosion has shown up after all, or that net pricing is slipping, would undercut the most important change in the story.
The cost side matters almost as much. Adjusted EBITDA totaled roughly $160 million in the first half, so the target of more than $310 million implies about $150 million over the back half, or a quarterly run rate a bit below the second quarter's $83 million. That gives Ironwood some cushion, but the STARS II Phase III trial began recruiting in June and management flagged a second-half ramp in research spending plus a modest increase in SG&A. Investors should want evidence that enrollment is moving, ideally with an update on the efforts to accelerate it, without spending overwhelming the EBITDA math. The balance sheet is another checkpoint: after repaying $200 million of convertible notes left cash at $79 million, management guided to gross debt below $300 million and leverage under 1x by year-end.
People questions also linger. The company lost its chief medical officer and its chief financial officer in the same quarter, and an interim CFO is running the numbers during a pivotal trial. Clean execution and a steady guidance message would go a long way toward easing continuity concerns.
Sentiment has warmed, swinging from 18.5% bearish before the last report to 10.5% bullish now, yet the share price tells a gloomier tale. At $3.61 the stock trades below its 200-day moving average of $4.00 and near the bottom of its post-earnings range of $3.38 to $4.60. That combination suggests the market is discounting the 2027 Medicare negotiated-price overhang more than this year's results. The report therefore needs to do more than hit the numbers. Ironwood has to show that Linzess demand is durable enough, and its cost discipline tight enough, to make the raised 2026 outlook look like a foundation rather than a peak.